// App-Quantinova.ai

SAT0145 : EFFICACY AND SAFETY OF UPADACITINIB MONOTHERAPY IN MTX-NAÏVE PATIENTS WITH EARLY ACTIVE RA RECEIVING TREATMENT WITHIN 3 MONTHS OF DIAGNOSIS: A POST-HOC ANALYSIS OF THE SELECT-EARLY

Researchers

Presenter

  • M. C. Kapetanovic

Principal Investigators

  • M. Andersson

  • A. Friedman

  • T. Shaw

  • Y. Song

  • D. Aletaha

  • M. H. Buch

  • U. Mller-Ladner

  • J. Pope

Medical Centers

  • Department of Pathology, Lund University and Skane University Hospital, Lund, Sweden

  • AbbVie AB, Solna, Sweden

  • AbbVie Ltd, Maidenhead, United Kingdom

  • Medical University of Vienna, Vienna, Austria

  • University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom

  • Justus-Liebig-University Giessen, Bad Nauheim, Germany

  • St Josephs Health Care, London, Canada

Locations

  • Sweden

  • United States

  • United Kingdom

  • Austria

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • Plasminogen Activator, Urokinase

  • Albumin/creatinine

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved